Ricevi le ultime notizie sulle azioni Lexicon Pharmaceuticals con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di LXRX

Ultime notizie per

LEXICON PHARMACEUTICALS INC

Lexicon Pharmaceuticals

Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.

Woman,Hand,Holding,Plus,Icon,For,The,Healthcare,Medical,Icon.

News

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

AMRN

LXRX

L&#39;analisi dell&#39;RSI segnala ipercomprato su due titoli dopo i forti rally recenti. Focus sui livelli tecnici e il rischio di una correzione.

2 azioni del settore sanitario che potrebbero crollare questo mese

Lexicon Pharmaceuticals, Inc. - Common Stock

Lexicon Pharmaceuticals Inc

Press Releases

Lexicon Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

Earnings

Lexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates

Lexicon Pharmaceuticals to Participate at Two Upcoming Investor Conferences

Analyst Ratings

Sotagliflozin Provides Consistent Relative Risk Reduction in Heart Failure and Major Cardiovascular Events Across All Age Ranges, Including Greater Than 75, in Data Presented at the European Society of Cardiology (ESC) 2025 Congress

Lexicon Pharmaceuticals Announces Presentation of Diabetic Peripheral Neuropathic Pain Patient Insights at PAINWeek 2025

Health Care

Lexicon Pharmaceuticals to Present New Preclinical Data on Pilavapadin in Chemotherapy-Induced Pain and Multiple Sclerosis Pain at NeuPSIG 2025

General

Lexicon Pharmaceuticals Announces Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes

Lexicon Pharmaceuticals to Present Additional Clinical Data on Pilavapadin at Three Upcoming Medical Meetings

Biotech

Pilavapadin Provides Meaningful Pain Reduction in Adults with Diabetic Peripheral Neuropathic Pain (DPNP) in Data Presented at the European Association for the Study of Diabetes (EASD) and NEUROdiab Annual Meetings

Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes

Absci

ADC Therapeutics

Astria Therapeutics

Autolus Therapeutics plc - American Depositary Shares

Autolus Therapeutics

COMPASS Pathways Plc - American Depository Shares

Compass Pathways

Compass Therapeutics, Inc. - Common Stock

Compass Therapeutics

Corvus Pharmaceuticals, Inc. - Common Stock

Corvus Pharma

CytomX Therapeutics

Emergent BioSolutions

Monte Rosa Therapeutics, Inc. - Common Stock

Monte Rosa Therapeutics

Gossamer Bio

I-MAB

Inhibrx Biosciences

Korro Bio

MoonLake Immunotherapeutics - Class A Ordinary Shares

MoonLake

Ocugen

Organogenesis Holdings

Prothena Corporation plc - Ordinary Shares

Prothena Corp

PureTech Health plc - American Depositary Shares

PureTech Health

RAPT Therapeutics

Regenxbio

Rigel Pharmaceuticals, Inc. - Common Stock

Rigel Pharmaceuticals

Solid Biosciences

Verastem

XOMA Royalty

HC Wainwright & Co.

Citigroup

Piper Sandler

Leerink Partners

Comments

Lexicon Pharmaceuticals Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO